Phio Pharmaceuticals
Phio’s proprietary RNA interference (RNAi) technology makes immune cells more effective in killing tumor cells.
Launch date
Employees
Market cap
$2.8m
Enterprise valuation
($6m) (Public information from Sep 2024)
Share price
$3.66 PHIO
Marlborough Massachusetts (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | 50.0m | 75.0m |
| % growth | - | - | - | - | - | - | 50 % |
| EBITDA | - | (8.7m) | (13.5m) | (11.5m) | (10.4m) | - | - |
| Profit | - | (8.8m) | (13.3m) | (11.5m) | (10.8m) | (9.6m) | 47.7m |
| % profit margin | - | - | - | - | - | (19 %) | 64 % |
| EV / revenue | - | - | - | - | - | 0.1x | 0.0x |
| EV / EBITDA | - | -1.8x | -1.0x | -0.4x | -0.2x | - | - |
| R&D budget | - | 4.4m | 8.9m | 7.0m | 6.3m | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| N/A | $300k | Grant | |
* | N/A | $16.4m | Private Placement VC |
* | $20.0m | Post IPO Equity | |
$10.4m | Post IPO Equity | ||
* | N/A | $4.9m | Post IPO Equity |
| N/A | $15.0m | Post IPO Equity | |
* | N/A | $1.0m | Post IPO Equity |
| N/A | $1.7m | Post IPO Equity | |
* | N/A | $8.0m | Post IPO Equity |
* | N/A | $14.0m | Private Placement VC |
* | N/A | $7.7m | Post IPO Equity |
* | N/A | $2.0m | Post IPO Equity |
* | N/A | $4.0m | Post IPO Equity |
* | N/A | $2.8m | Post IPO Equity |
* | $621k | Post IPO Equity | |
* | N/A | $3.1m | Post IPO Equity |
| Total Funding | $30.7m | ||
